On September 8, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and China during September 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These speaking engagements position Akari’s proprietary PH1 ADC payload technology in front of leading global pharmaceutical and biotechnology companies focused on ADCs, potential strategic partners, and healthcare investors at a time when the industry is increasingly focused on novel payloads and next-generation ADC technologies.
Through these various presentations and expert panels, Akari expects to highlight the potential of its PH1 platform to enable differentiated ADCs, discuss emerging strategies for improving ADC efficacy and safety, and explore opportunities for global R&D collaboration, platform partnerships, and its pipeline expansion.
"We believe being selected to actively participate in these conferences and discussions reflects growing interest in novel ADC payload technologies and key unmet needs around ADC therapy sequencing," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "These key conferences in September give us an exceptional opportunity to put the PH1 ADC payload and Akari’s next-generation ADC strategy in front of potential partners across pharma and biotechnology companies and strategic healthcare investors. We believe the next wave of ADC innovation will be driven in significant part by differentiated payloads, and we are excited to showcase the potential and opportunity for Akari’s ADC payload targeting RNA splicing. As we advance AKTX-101 toward the clinic, these forums also provide an important opportunity to deepen strategic relationships and demonstrate the broader potential of our PH1 payload platform."
Oncology & Immunology Innovation Partnering & Licensing Summit
Dates: September 9–10, 2026
Location: Boston, Massachusetts
Panel: Thursday, September 10, 2026, at 8:30 AM ET
Panel Title: Reflecting on the First Attempts with Novel Payloads & What We Are Doing Differently Now
Session: Novel Payloads & Combinations as the New Value Driver in ADCs
Participant: Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics
Mr. Gaslightwala will participate in a discussion focused on the evolution of novel ADC payloads and how emerging technologies could help address limitations associated with current ADCs. The session places Akari directly within a broader industry conversation around novel payloads as potential drivers of the next generation of ADC innovation.
H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14–16, 2026
Location: New York, NY
Format: Pre-recorded fireside chat and investor meetings
The fireside chat will provide an opportunity for management to discuss Akari’s PH1 payload platform, advancement of AKTX-101 and the Company’s broader strategy for next-generation ADC development.
The pre-recorded fireside chat will be available beginning September 11, 2026. Access the fireside chat here.
Investors interested in meeting with Akari management during the conference are encouraged to contact their H.C. Wainwright representative to request a meeting.
BioCon China 2026
Dates: September 15–16, 2026
Location: Shanghai, China
Keynote Presentation: Tuesday, September 15, 2026, from 10:45–11:15 AM (CST)
Presentation Title:
From Big Pharma to Biotech: Differentiated Value of Next-Gen ADCs and China Collaboration Opportunities
Participant: Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics
In addition to the keynote presentation, Mr. Gaslightwala will participate in a speaker panel titled, Opportunities, Partnership Options & Critical Success Factors for Global Collaboration of Chinese‑Innovated Assets: A Multinational Pharma Perspective, focused on the evolving value of differentiated ADC technologies and opportunities for collaboration between global biotechnology companies and the Chinese biopharmaceutical industry.
2026 Global XDC Innovation Conference
Dates: September 17–19, 2026
Location: WuXi, China
Presentation: Saturday, September 19, 2026,
Presentation Title: Novel ADC Payloads Designed to Target RNA Splicing to Drive Differentiated Efficacy and Safety and New Options for ADC Therapy Sequencing
Session: Session IV – XDC New Modalities: BsADC, Dual-Payload ADC, AOC, and Beyond
Participant: Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics
At the Global XDC Innovation Conference, Akari will specifically showcase its approach to developing ADC payloads designed to target RNA splicing and the potential implications for efficacy, safety and therapeutic sequencing. The presentation will position PH1 within the emerging landscape of next-generation ADC technologies being developed.
5th Annual ROTH Healthcare Opportunities Conference
Date: September 29, 2026
Location: New York, New York
Format: Investor meetings
Akari will conclude its September conference schedule at the 5th Annual ROTH Healthcare Opportunities Conference, where management expects to meet with healthcare investors and discuss the Company’s PH1 platform, advancement of AKTX-101 and broader ADC development strategy.
Investors interested in meeting with Akari management during the conference are encouraged to contact their ROTH representative to request a meeting.
Advancing a Differentiated Approach to the Next Generation of ADCs
Akari’s participation across these conferences comes as the Company advances AKTX-101, its lead Trop2-targeting ADC, through IND-enabling development toward a planned first-in-human clinical trial by mid-2027.
Unlike ADCs utilizing traditional microtubule inhibitor or DNA-damaging payloads, Akari’s proprietary PH1 payload is designed to target RNA splicing, providing a differentiated mechanism intended to induce cancer cell death while activating both innate and adaptive immune responses.
Beyond AKTX-101, Akari is developing AKTX-102, targeting CEACAM5, and is exploring the broader potential of its PH1 technology across next-generation ADC architectures and development strategies.
(Press release, Akari Therapeutics, SEP 8, 2026, View Source [SID1234670614])